United Kingdom
Founded in 2010, Redx Pharma is a clinical-stage biotechnology company headquartered in the United Kingdom. The company is dedicated to the discovery and development of novel, small molecule, targeted therapeutics for treating cancer and fibrotic diseases. Its strength lies in its team of world-class scientists located at Alderley Park, the UK's largest life science campus.
Redx Pharma's strategic focus is underscored by its lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), currently in a Phase 2 clinical trial for idiopathic pulmonary fibrosis. Additionally, their second candidate, RXC008, caters to fibrostenotic Crohn’s disease, initiating a Phase 1 trial in Q1 2024. The company's lead oncology product, the Porcupine inhibitor, zamaporvint (RXC004), has been in a Phase 2 program since November 2021.
The company last raised £35.00M through a Post-IPO Equity investment on 19 May 2022. Redx's robust background in medicinal chemistry and translational science positions it as a promising player in the biotechnology sector, particularly for investors interested in innovative cancer and fibrosis treatments.
